Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without TP53 Aberrations

被引：11

作者：

Jain, Nitin ^{[1
]}

Thompson, Philip A. ^{[1
]}

Burger, Jan A. ^{[1
]}

Ferrajoli, Alessandra ^{[1
]}

Borthakur, Gautam ^{[2
]}

Bose, Prithviraj ^{[1
]}

Estrov, Zeev E. ^{[1
]}

Kadia, Tapan M. ^{[1
]}

Takahashi, Koichi ^{[1
]}

Garg, Naveen ^{[3
]}

Wang, Xuemei ^{[4
]}

Kanagal-Shamanna, Rashmi ^{[5
]}

Patel, Keyur ^{[5
]}

Lopez, Wanda ^{[1
]}

Ayala, Ana ^{[1
]}

Plunkett, William ^{[6
]}

Gandhi, Varsha ^{[6
]}

Kantarjian, Hagop M. ^{[1
]}

O'Brien, Susan M. ^{[7
]}

Keating, Michael J. ^{[1
]}

Wierda, William G. ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[2] Univ Texas MD Anderson Canc Ctr, Sect Mol Hematol & Therapy, Dept Leukemia, Houston, TX 77030 USA

[3] Univ Texas MD Anderson Canc Ctr, Dept Diagnost Radiol, Houston, TX 77030 USA

[4] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA

[5] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA

[6] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA

[7] Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Irvine, CA USA

来源：

BLOOD | 2018年 / 132卷

关键词：

D O I：

10.1182/blood-2018-185

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

695

引用

页数：4

共 50 条

[11] IBRUTINIB, FLUDARABINE, CYCLOPHOSPHAMIDE, AND OBINUTUZUMAB (GA101) (IFCG) FOR PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH MUTATED IGHV AND NON-DEL(17P)
Jain, N.
Thompson, P.
Burger, J.
Borthakur, G.
Bose, P.
Estrov, Z.
Ferrajoli, A.
Gandhi, V.
Plunkett, W.
Lopez, W.
Kantarjian, H.
O'Brien, S.
Keating, M.
Wierda, W.
HAEMATOLOGICA, 2017, 102 : 171 - 171
[12] Long-Term Outcome of Treatment-Naive and Relapsed/Refractory Patients with CLL and TP53 Aberrations Treated with Ibrutinib, with or without Rituximab
Sivina, Mariela
Kim, Ekaterina
Wierda, William G.
Ferrajoli, Alessandra
Jain, Nitin
Thompson, Philip A.
Estrov, Zeev E.
Kantarjian, Hagop
Keating, Michael J.
Burger, Jan A.
BLOOD, 2021, 138 : 3734 - +
[13] THERAPEUTIC USE OF IBRUTINIB IN PATIENTS WITH MUTATED LLC TP53
Adrian, Segura D.
Natalia, Espinosa L.
Laura, Lacalle A.
Marta, Villalba M.
Gonzalo, Ferrer G.
Gonzalo, Caballero N.
Ana Cristina, Godoy M.
Araceli, Rubio M.
Pilar, Delgado B.
HAEMATOLOGICA, 2016, 101 : 335 - 335
[14] A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease
Best, O. G.
Gardiner, A. C.
Davis, Z. A.
Tracy, I.
Ibbotson, R. E.
Majid, A.
Dyer, M. J. S.
Oscier, D. G.
LEUKEMIA, 2009, 23 (01) : 212 - 214
[15] A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease
O G Best
A C Gardiner
Z A Davis
I Tracy
R E Ibbotson
A Majid
M J S Dyer
D G Oscier
Leukemia, 2009, 23 : 212 - 214
[16] CLONAL EVOLUTION IN CLL IS ASSOCIATED WITH AN UNMUTATED IGHV STATUS, MUTATED TP53 AND SHORTER SURVIVAL
Haferlach, C.
Jeromin, S.
Nadarajah, N.
Zenger, M.
Kern, W.
Haferlach, T.
HAEMATOLOGICA, 2016, 101 : 224 - 224
[17] OBINUTUZUMAB PLUS CHLORAMBUCIL VERSUS IBRUTINIB IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA WITHOUT TP53 DISRUPTIONS. A CAMPUS CLL STUDY
Visentin, A.
Pravato, S.
Mauro, F. R.
Pietrasanta, D.
Fresa, A.
Vitale, C.
Ciolli, S.
Cassin, R.
Cibien, F.
Sportoletti, P.
Gentile, M.
Rigolin, G. M.
Quaglia, F. M.
Murru, R.
Gozzetti, A.
Molica, S.
Marchetti, M.
Scarfo, L.
Guardalben, E.
Avitabile, A.
Reda, G.
Coscia, M.
Laurenti, L.
Pizzolo, G.
Semenzato, G.
Foa, R.
Cuneo, A.
Trentin, L.
HAEMATOLOGICA, 2021, 106 (10) : 62 - 63
[18] Telomere length predicts response to Fludarabine, Cyclophosphamide, Rituximab and is particularly informative for IGHV-mutated CLL patients
Pepper, Chris
Norris, Kevin
Hillmen, Peter
Fegan, Christopher
Baird, Duncan
LEUKEMIA & LYMPHOMA, 2017, 58 : 228 - 230
[19] Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/small lymphocytic leukemia with or without TP53 aberrations: a prospective real-world study in Chinese cohort
Zhu, Huayuan
Miao, Yi
Sha, Yeqin
Xia, Yi
Qin, Shuchao
Jiang, Rui
Dai, Luomengjia
Shen, Hui
Qiu, Tonglu
Wu, Wei
Ding, Chongyang
Wu, Yujie
Fan, Lei
Xu, Wei
Li, Jianyong
LEUKEMIA & LYMPHOMA, 2023, 64 : S93 - S94
[20] Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/small lymphocytic leukemia with or without TP53 aberrations: a prospective real-world study in Chinese cohort
Miao, Yi
Sha, Yeqin
Xia, Yi
Qin, Shuchao
Jiang, Rui
Dai, Luomengjia
Shen, Hui
Qiu, Tonglu
Wu, Wei
Qiu, Jingyan
Yang, Yilian
Ding, Chongyang
Wu, Yujie
Fan, Lei
Xu, Wei
Li, Jianyong
Zhu, Huayuan
BLOOD CANCER JOURNAL, 2023, 13 (01)

← 1 2 3 4 5 →